Comparing the Efficacy of Various Treatment Strategies for Patients With Advanced Triple-Negative Breast Cancer: An Umbrella Review - PubMed
8 hours ago
- #umbrella review
- #treatment efficacy
- #triple-negative breast cancer
- Chemotherapy (CT) is the standard first-line treatment for advanced triple-negative breast cancer (aTNBC).
- Targeted therapies (TT) and immune checkpoint inhibitors (ICI) are emerging as innovative treatments.
- TT and ICI groups showed superior progression-free survival (PFS) compared to CT [ICI: HR = 0.81; TT: HR = 0.68].
- TT group demonstrated better overall survival (OS) than CT [HR = 0.77].
- Sacituzumab govitecan (SG) monotherapy and trilaciclib combined with chemotherapy (TRI_CT) significantly improved PFS and OS.
- SG and TRI_CT are recommended as first-choice treatments for aTNBC patients.
- The review is high-quality evidence, rated using AMSTAR 2 and GRADE.
- Study follows PRISMA guidelines and is registered with PROSPERO.